Profile: Anavex Life Sciences Corp
BHI Company Directory Profile
ANAVEX LIFE SCIENCES CORP
14 Rue Kleberg
CH-1201 Geneva
Switzerland
www.anavex.com
info@anavex.com
ANAVEX LIFE SCIENCES Corp. (AVXL.OB) is engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases, utilizing its proprietary drug discovery Sigmaceptor™ Technology Platform, consisting of a fairly new class of receptors, (sigma receptors), involved in the modulation of multiple cellular biochemical signaling pathways.
ANAVEX portfolio involves eleven new sigma ligands in late pre-clinical stage that target therapeutic areas of CNS and Cancer. These product candidates are expected to enter clinical trials within 2008.
ANAVEX’s Sigmaceptor-N program involves the discovery and development of novel and original drug candidates, targeting neurological and neurodegenerative diseases with urgent unmet medical needs such as, Alzheimer’s disease, Epilepsy, Depression, Multiple Sclerosis, Parkinson’s disease e.t.c. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence of anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anti-convulsive, anti-depressant and anxiolytic properties.
ANAVEX’s Sigmaceptor-C program involves the discovery and development of novel and original drug candidates targeting cancer. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as colon, prostate, breast and lung.
Preliminary results from in vivo studies in xenograft models have shown that ANAVEX lead compounds cause significant delay of tumor growth, suggesting a potent in vivo anticancer activity by inducing anoikis in a dose and time dependent manner.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
ANAVEX LIFE SCIENCES CORP14 Rue Kleberg
CH-1201 Geneva
Switzerland
www.anavex.com
info@anavex.com
ANAVEX LIFE SCIENCES Corp. (AVXL.OB) is engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases, utilizing its proprietary drug discovery Sigmaceptor™ Technology Platform, consisting of a fairly new class of receptors, (sigma receptors), involved in the modulation of multiple cellular biochemical signaling pathways.
ANAVEX portfolio involves eleven new sigma ligands in late pre-clinical stage that target therapeutic areas of CNS and Cancer. These product candidates are expected to enter clinical trials within 2008.
ANAVEX’s Sigmaceptor-N program involves the discovery and development of novel and original drug candidates, targeting neurological and neurodegenerative diseases with urgent unmet medical needs such as, Alzheimer’s disease, Epilepsy, Depression, Multiple Sclerosis, Parkinson’s disease e.t.c. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence of anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anti-convulsive, anti-depressant and anxiolytic properties.
ANAVEX’s Sigmaceptor-C program involves the discovery and development of novel and original drug candidates targeting cancer. The company’s lead drug candidates exhibit high affinity to sigma receptors with strong evidence for selective apoptosis of cancerous cells without affecting healthy cells, anti-metastatic and low toxicity properties in various types of cancer such as colon, prostate, breast and lung.
Preliminary results from in vivo studies in xenograft models have shown that ANAVEX lead compounds cause significant delay of tumor growth, suggesting a potent in vivo anticancer activity by inducing anoikis in a dose and time dependent manner.
This is a BioHealth Investor company profile. Promote your company, learn how...
____________________
posted by Nico at
5:51 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home